More Pharma Firms In China Diversify With Direct Sales Of Consumer Products
This article was originally published in The Tan Sheet
Under the influence of the changing pharmaceutical policy environment, China's pharmaceutical companies are experiencing a development bottleneck. Upgrading to new business model and finding new ways of doing so have become a reality of choice for many companies. More and more pharmas are tapping into the opportunities of direct sale, including A-share market-listed and state-owned companies, bringing total to 10 pharmas.